Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11

The AWARD‐11 trial demonstrated the safety and efficacy of dulaglutide 3.0 and 4.5 mg compared to dulaglutide 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin. This post hoc analysis examined the change from baseline in glycated haemoglobin (HbA1c) and proportions of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan P., Bonora, Enzo, Cox, David A., Bethel, M. Angelyn, Kwan, Anita Y.M., Raha, Sohini, Malik, Raleigh E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292947/
https://www.ncbi.nlm.nih.gov/pubmed/34463420
http://dx.doi.org/10.1111/dom.14533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292947/
https://www.ncbi.nlm.nih.gov/pubmed/34463420
http://dx.doi.org/10.1111/dom.14533

Ejemplares similares